Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Belrestotug |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Belrestotug
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
Bemarituzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Bemarituzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Bezuclastinib |
Selective KIT D816V Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Bezuclastinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Selective KIT D816V Inhibitor |
||||
BGB-16673 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
BGB-16673 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
BI-847325 |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
BI-847325
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
BMS-986156 (GITR) |
Costimulatory / Bispecific Agent | Solid Tumour | ||
|
Molecule
BMS-986156 (GITR)
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
||||
BMS-986205 (Linrodostat) |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
BMS-986205 (Linrodostat)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
BMS-986258 |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
BMS-986258
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
CFT7455 (Cereblon Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
CFT7455 (Cereblon Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Cibisatamab |
CD47 (Macrophage Checkpoint) Inhibitor | Hematologic | ||
|
Molecule
Cibisatamab
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
||||
Cixutumumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Cixutumumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Cobolimab |
TIM-3 / LAG-3 / TIGIT Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Cobolimab
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
||||
BelrestotugImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
BemarituzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
BezuclastinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Selective KIT D816V Inhibitor |
|
BGB-16673 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
BI-847325Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
BMS-986156 (GITR)Immunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Costimulatory / Bispecific Agent |
|
BMS-986205 (Linrodostat)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
BMS-986258Immunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|
CFT7455 (Cereblon Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
CibisatamabImmunotherapy (Investigational) |
|
|
Therapeutic Category
Immunotherapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
CD47 (Macrophage Checkpoint) Inhibitor |
|
CixutumumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
CobolimabImmunotherapy (Investigational Checkpoint) |
|
|
Therapeutic Category
Immunotherapy (Investigational Checkpoint)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
TIM-3 / LAG-3 / TIGIT Inhibitor |
|